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Background: In comparison to the general population, people who are homeless have poorer 
health and health-related outcomes, including for vaccine-preventable diseases. Vaccination is 
safe, effective and cost-effective, and many vaccination guidelines specifically recommend 
vaccination in people who are homeless. This systematic review will identify interventions 
which are effective in delivering vaccination to, and/or at improving vaccination rates in, people 
who are homeless. 
 
Methods/Design: This systematic review is presented according to the Preferred Reporting Items 
for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Searches will be undertaken 
on eight electronic databases, using combinations of search terms and subject headings or index 
terms. Citation chaining will also be undertaken. Literature will be screened for relevance against  
inclusion/exclusion criteria firstly by title/abstract and secondly by full text. The selected studies 
will be assessed for quality using an evidence-based tool appropriate to their methods. Data 
relevant to the topic will be extracted and examined using meta-analysis and narrative synthesis.   
 
Discussion: This systematic review will address an important gap in the literature about 
vaccination in people who are homeless. The review’s findings are particularly relevant 
considering the current coronavirus disease (COVID-19) pandemic, which is likely to be 
managed through vaccination.  
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1.  Background 
1.1  Overview of homelessness  
There is no universal definition of ‘homelessness’; however, it is generally agreed to occur 
when a person lacks access to suitable housing (Organisation for Economic Cooperation and 
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Development, 2019). People who are homeless include those who are unsheltered, as well as 
those staying in households other than their own, in overcrowded, substandard, untenable or 
unsafe housing, and in shelters (Organisation for Economic Cooperation and Development, 
2019). Among OECD countries for which recent data is available, rates of homelessness as a 
percentage of total population range from 0.004% (N=4,560) in Japan to 0.940% (N=41,200) in 
New Zealand (Organisation for Economic Cooperation and Development, 2019). In Australia, 
where the authors are located, approximately 0.480% (N=116,400) of people are homeless 
(Australian Bureau of Statistics, 2016). In one-third of OECD countries, including in Australia, 
homelessness is increasing (Organisation for Economic Cooperation and Development, 2019).  
 
1.2  Health disparities and vaccine-preventable diseases in people who are homeless 
In comparison to the general population, people who are homeless experience poorer health 
and health-related outcomes. People who are homeless are at greater risk of developing a range 
of mental and physical illnesses, including vaccine-preventable diseases such as hepatitis 
(Hosseini & Ding, 2018; Noska et al., 2017; Peak et al., 2019), pneumococcal disease (Lemay et 
al., 2019; McKee et al., 2018; Mosites et al., 2019) and tuberculosis (Bamrah et al., 2013; Khan 
et al., 2011; Lee et al., 2013; Romaszko et al., 2013). Once ill, people who are homeless have a 
greater likelihood of hospitalisation, intensive care unit (ICU) admission, and death (Lewer et al., 
2020). 
There are a number of reasons for these outcomes. In comparison to the general population, 
people who are homeless are more likely to have multiple chronic comorbidities (Lebrun-Harris 
et al., 2013), high rates of problematic substance use (Krupski et al., 2015; Lebrun-Harris et al., 
2013), and poor nutrition (Fallaize et al., 2017). People who are homeless often live in outdoor, 
informal and highly-congregate settings, among transient populations, and without access to 
adequate hygiene facilities (Tsai & Wilson, 2020). Further, people who are homeless often have 
limited access to healthcare and, subsequently, unmet health needs (Aldridge et al., 2019; Elwell-
Sutton et al., 2017). These factors all contribute to illness and facilitate the spread of disease.  
 
1.3  Overview of vaccines and vaccination 
A vaccine is a substance which stimulates the immune system to produce antibodies against 
one or more pathogen(s), thereby reducing the likelihood of future infection with those 
pathogen(s) (Federman, 2014). To date, vaccines have been developed for >30 different 
pathogens (Delany et al., 2014). Vaccines may be manufactured to contain whole pathogens (live 
attenuated or inactivated), parts of pathogens, adjuvants and/or toxoids (Vetter et al., 2017). They 
may be delivered intramuscularly, intradermally, subcutaneously, intranasally or orally, etc., and 
in the form of a single dose, a multiple-dose schedule or an annual booster (Vetter et al., 2017). 
Systematic reviews show that vaccines – including those for infectious diseases common in 
people who are homeless, such as hepatitis (Ott et al., 2012; Stuurman et al., 2017; van den Ende 
et al., 2017; Whitford et al., 2018), pneumococcal disease (Falkenhorst et al., 2017; McLaughlin 
et al., 2019), and tuberculosis (Roy et al., 2014) – are safe, effective and cost-effective. Vaccines 
protect not only the person vaccinated, but also the broader population by facilitating population 
immunity (Orenstein & Ahmed, 2017). Subsequently, most OECD nations have guidelines about 
vaccination, and many – including Australia’s (Australian Government - Department of Health, 
2020) – make specific recommendations about vaccination in people who are homeless.  
 
Social Science Protocols, December 2020, 1-15.  
http://dx.doi.org/10.7565/ssp.v3.5190 
   
3 
1.4  Vaccination in people who are homeless 
There are multiple complexities associated with delivering vaccination to people who are 
homeless. As noted earlier, people who are homeless frequently have limited access to 
healthcare. Further complicating this is the fact that public health infrastructure to support 
vaccination in adults, particularly those from hard-to-reach groups, is often inadequate (Poulos et 
al., 2010). Vaccinations in adults are often minimally reimbursed, and costs may be prohibitive 
for people in low-income groups (Doroshenko et al., 2012; Poulos et al., 2010). Research shows 
that people who are homeless are often ambivalent about vaccination, and that it may be a low 
priority in their lives (Doroshenko et al., 2012; Poulos et al., 2010). Although there are no 
systematic reviews on the topic, it is accepted that – in comparison to the general population – 
vaccination coverage for a range of diseases is lower in people who are homeless (Wood, 2012). 
To date, there are no existing systematic reviews about effective interventions to deliver 
vaccination to, and improve vaccination rates in, people who are homeless. Subsequently, there 
is a lack of evidence to inform practice in this area. It is reasonable to assume this may reinforce 
the poorer health and health-related outcomes experienced by people who are homeless.  
 
1.4  Aim of the review  
The aim of the proposed systematic review is to address the gaps in the existing literature 
about vaccination in people who are homeless. The review will achieve this by: (1) identifying, 
(2) analysing the characteristics of, and (3) evaluating the outcomes of, interventions to deliver 
vaccination to, and/or improve vaccination rates in, people who are homeless.  
 
1.5  Review question 
This review will answer the questions: (1) What interventions have been implemented to 
deliver vaccination to and/or improve vaccination rates in people who are homeless?, (2) What 
are the characteristics of these interventions?, and (3) What are the outcomes of these 
interventions?   
 
2.  Methods/Design 
2.1  Study design 
A systematic review of the existing research literature will be undertaken. Preliminary 
scoping searches have been completed to inform this protocol (e.g. to determine type and extent 
of literature available, effective search terms, suitable databases/limiters/data extraction items, 
etc.). This protocol has been reported using the Preferred Reporting Items for Systematic Review 
and Meta-Analysis Protocols (PRISMA-P) guidelines (Shamseer et al., 2015) (Additional File 
#1).  
 
2.2  Participants, intervention design and focus, and outcomes of interest  
Eligibility criteria for this review were developed using the PICO (population, intervention, 
comparator, outcome) framework. Application of the framework to the topic is as follows: 
 Population: people who are homeless:  
o The review will use the definition of ‘homeless’ cited in Section 1.1. 
o The review will consider interventions for homeless adults, youth and/or children.  
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 Intervention: any intervention implemented to: (1) deliver vaccination to, and/or (2) 
improve vaccination rates in, people who are homeless:  
o The review will use the definition of ‘vaccination’ cited in Section 1.3; the review 
will consider any type of vaccination, for any type of vaccine-preventable disease.  
o To ‘deliver vaccination’ means to vaccinate people who are homeless. 
o An ‘improvement in vaccination rates’ may be measured in a variety of ways (e.g. 
as an increase in the number (N) or percentage (%) of people being vaccinated, 
N/% completing a vaccination schedule, N/% accepting (versus declining) 
vaccination, etc.). However, a study considered for inclusion may describe a 
vaccination intervention without measuring an improvement in vaccination rates. 
 Comparator: standard approaches to vaccination delivery, or no vaccination delivery. 
 Outcome: (1) the intervention’s characteristics, and (2) the interventions’ outcomes; a 
comprehensive list of outcomes is provided in Section 2.6. 
 
Systematic reviews, randomised control trials and direct comparative studies will be the focus 
of this review. In the absence of these, all other study types will be considered, including 
qualitative, quantitative and mixed-methods studies. Literature will be considered if it reports on 
a study undertaken in Australia, where the authors are located, or in a similar international 
context (i.e. New Zealand, Western Europe [including the UK], North America [including the 
US and Canada], etc.). Only literature published in English, in full-text and in a peer-reviewed 
journal will be considered. Literature will not be limited by date.  
 
2.3  Search strategy 
The searches will use two groups of keywords: (1) those related to ‘homelessness’, and (2) 
those related to ‘vaccination’ (including ‘immunisation’). Index terms and subject headings will 
be used, where these are available on the databases. Boolean operators, parentheses and 
truncation will be applied where required. Sample search strategies are provided in Additional 
File #2. 
 
2.4  Information sources 
The searches will be undertaken on the following electronic databases: CINAHL Complete 
(via Ebscohost), ClinicalTrials.gov, Cochrane Library, Embase, MEDLINE (via Ebscohost), 
PsycInfo (via Ovid), Scopus and Web of Science (via Clarivate Analytics). The reference lists of 
each piece of literature selected for inclusion in the review will also be manually searched.  
 
2.5 Data collection  
The search results will be exported into EndNote X9. Using EndNote’s ‘find duplicate’ 
function, duplicate items will be removed. The items will then be screened against the eligibility 
criteria outlined in Section 2.2 in two steps: (1) for all items: by reading the title/abstract, then 
(2) for the remaining items: by reading the full text. Each step will be completed by one 
researcher and checked by a second researcher; where needed, agreement will be achieved 
through discussion or by involving a third researcher. A Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) chart (Moher et al., 2009) will be used to 
record the selection process.  
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2.6  Data extraction  
Data will be extracted into an electronic table. Data extraction will be completed by one 
researcher and checked by a second researcher; where needed, agreement will be achieved 
through discussion or by involving a third researcher. The data extracted will include:  
 Data about the study – the author/s; publication date; country/ies; purpose/aim; 
design/methods; recruitment/sampling procedures; randomisation procedures (if 
relevant); data collection procedures; data analysis procedures; study funding; etc.  
 Data about the study participants – the sample size; inclusion/exclusion criteria; baseline 
characteristics including type of homelessness experienced (e.g. sheltered/unsheltered, 
short-/medium-/long-term, etc.); risk factors for vaccine-preventable diseases; etc.  
 Data about the intervention and its characteristics – the provider/s; purpose/aim (e.g. 
routine prevention, response to outbreak, etc.); site/setting (e.g. clinic, outreach, etc.); 
size; disease/s targeted; type/s of vaccines delivered;  staffing; co-interventions (e.g. 
reminders, health education, etc.); duration including length of participant follow-up; 
resource requirements; vaccine funding (e.g. self-funded, government-funded), etc.  
 Data about the outcomes of the intervention – including improvement in vaccination 
rates, as defined in Section 2.2. Secondary outcomes will include: (1) determinants of 
vaccination uptake, and (2) challenges/barriers to intervention delivery. The review will 
not consider outcomes associated with serological testing for immunity, or rates of post-
vaccination illness, as these measure vaccine (rather than intervention) effectiveness.  
 
2.7  Quality assessment 
Literature selected for inclusion will be evaluated using an appropriate evidence-based tool:   
 For systematic reviews: the revised Assessing the Methodological Quality of Systematic 
Reviews (AMSTAR 2) tool (Shea et al., 2017) 
 For randomised and quasi-randomised-controlled trials: the revised Cochrane Risk-of-
Bias Tool for Randomised Controlled Trials (RoB 2) (Sterne et al., 2019)  
 For cohort studies: the Risk of Bias in Non-Randomised Studies of Interventions 
(ROBINS-1) tool (Cochrane Methods, ND) 
 For cross-sectional studies: the Appraisal Tool or Cross-Sectional Studies (AXIS) 
(Downes et al., 2016) 
 For qualitative studies: the Joanna Briggs Institute (JBI) Critical Appraisal Checklist for 
Qualitative Research (Joanna Briggs Institute (JBI), 2019) 
 
2.8  Data synthesis 
If possible, a meta-analysis will be undertaken to evaluate the outcomes of the interventions. 
If a meta-analysis is not possible, and for all other data, a narrative synthesis will be completed.  
 
2.9  Ethics 




Social Science Protocols, December 2020, 1-15.  
http://dx.doi.org/10.7565/ssp.v3.5190 
   
6 
3. Discussion 
This systematic review addresses an important gap in the existing literature about vaccination 
in people who are homeless. The review is also particularly relevant in the context of the current 
coronavirus disease (COVID-19) pandemic. Research among residents of homeless shelters in 
the United States in March/April/May 2020 identifies COVID-19 infection rates of between 
2.1% and 67.0%, far higher than in the general population (Baggett et al., 2020; Ghinai et al., 
2020; Imbert et al., 2020; Mosites et al., 2020; Yoon et al., 2020). Modelling studies show that 
people who are homeless are significantly more likely than those in the general population to be 
hospitalised, to be admitted to ICUs, and to die from COVID-19 (Culhane, 2020; Lewer et al., 
2020). People who are homeless may also be disproportionately impacted by the negative 
socioeconomic impacts of COVID-19 responses (Perri et al., 2020). 
The best option for reducing the enormous health and socioeconomic impacts of COVID-19 – 
both in people who are homeless, and in the general population – is a vaccine (World Health 
Organization, 2020b). At mid-October 2020 there are 44 vaccine candidates undergoing clinical 
evaluation (World Health Organization, 2020a). This review will provide evidence about how a 
COVID-19 vaccine, if developed, and other vaccines can be delivered to people who are 
homeless in an effective and cost-effective way. By providing evidence to inform practice, the 
review may contribute to improving the health and health-related outcomes of people who are 
homeless.  
However, the limitations of this systematic review must also be considered. In the scoping 
searches undertaken, few high-quality studies (e.g. randomised controlled trials, direct 
comparative studies, etc.) were identified. The studies which were identified are heterogeneous, 
and this may prevent meta-analysis and cause difficulties in evaluating and comparing the effects 
of the interventions. Further, there is no scope in this project to examine literature published in 
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Checklist item Location in 
submission 
ADMINISTRATIVE INFORMATION  
Title:    
 Identification 1a Identify the report as a protocol of a systematic review Title 
 Update 1b If the protocol is for an update of a previous systematic review, identify as such N/A 
Registration 2 If registered, provide the name of the registry (such as PROSPERO) and registration number N/A 
Authors:    
 Contact 3a Provide name, institutional affiliation, e-mail address of all protocol authors; provide physical 
mailing address of corresponding author 
Authors and 
Affiliations 
 Contributions 3b Describe contributions of protocol authors and identify the guarantor of the review Authors’ 
Contributions 
Amendments 4 If the protocol represents an amendment of a previously completed or published protocol, identify 
as such and list changes; otherwise, state plan for documenting important protocol amendments 
N/A 
Support:   
Funding 
Statement 
 Sources 5a Indicate sources of financial or other support for the review 
 Sponsor 5b Provide name for the review funder and/or sponsor 
Role of sponsor 
or funder 
5c Describe roles of funder(s), sponsor(s), and/or institution(s), if any, in developing the protocol 
N/A 
INTRODUCTION  
Rationale 6 Describe the rationale for the review in the context of what is already known Sections, 1.1, 
1.2, 1.3 
Objectives 7 Provide an explicit statement of the question(s) the review will address with reference to 
participants, interventions, comparators, and outcomes (PICO) 
Sections 1.4, 
1.5 
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8 Specify the study characteristics (such as PICO, study design, setting, time frame) and report 
characteristics (such as years considered, language, publication status) to be used as criteria for 




9 Describe all intended information sources (such as electronic databases, contact with study authors, 
trial registers or other grey literature sources) with planned dates of coverage 
Section 2.4 
Search strategy 10 Present draft of search strategy to be used for at least one electronic database, including planned 




Study records:    
 Data 
management 




11b State the process that will be used for selecting studies (such as two independent reviewers) 
through each phase of the review (that is, screening, eligibility and inclusion in meta-analysis) 
Section 2.5 
 Data collection 
process 
11c Describe planned method of extracting data from reports (such as piloting forms, done 
independently, in duplicate), any processes for obtaining and confirming data from investigators 
Section 2.6 
Data items 12 List and define all variables for which data will be sought (such as PICO items, funding sources), 




13 List and define all outcomes for which data will be sought, including prioritization of main and 
additional outcomes, with rationale 
Section 2.6 
Risk of bias in 
individual studies 
14 Describe anticipated methods for assessing risk of bias of individual studies, including whether this 
will be done at the outcome or study level, or both; state how this information will be used in data 
synthesis 
Section 2.7 
Data synthesis 15a Describe criteria under which study data will be quantitatively synthesised 
Section 2.8 
15b If data are appropriate for quantitative synthesis, describe planned summary measures, methods of 
handling data and methods of combining data from studies, including any planned exploration of 
consistency (such as I2, Kendall’s τ) 
15c Describe any proposed additional analyses (such as sensitivity or subgroup analyses, meta-
regression) 
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15d If quantitative synthesis is not appropriate, describe the type of summary planned 
Meta-bias(es) 16 Specify any planned assessment of meta-bias(es) (such as publication bias across studies, selective 

















Search #1: homeless*  
 
Search #2: (vaccin* OR immuni*) 
______________________________________________________________________ 
 
CINAHL Complete with subject headings: (MM "homeless persons" OR MM "homelessness" 
OR Search #1) AND (MH "immunization+" OR Search #2) 
 
Clinical Trials.gov (Search #1) AND (Search #2) 
 
Cochrane Library: (Vaccination [MeSH] AND Search #1) AND (Homeless persons [MeSH] 
AND Search #2) 
 
Embase with index terms: ('homeless person'/exp OR homeless*) AND ('immunization'/exp 
OR Search #2)  
 
MEDLINE (via EBSCOhost) with subject headings: (MH "homeless persons+" OR 
homeless*) AND (MH "vaccination+" OR Search #2) 
 
PsycInfo: [(exp Homeless/) OR Search #1] AND [(exp Immunization/) OR Search #2] 
 
Scopus: (Search #1) AND (Search #2) 
 
Web of Science: (Search #1) AND (Search #2) 
 
 
Note: The term ‘vaccination’ refers to receiving a vaccine, whereas the term ‘immunisation’ 
refers to the process of receiving a vaccine and developing immunity to the pathogen/s the 
vaccination covers (Australian Government - Department of Health, 2018). Both terms are 
used interchangeably in the literature. Therefore, both terms are used in the searches.  
 
